Navigation Links
Newly identified mechanism for silencing genes points to possible anti-cancer strategies

Genes provide the instructions used by the individual cells to produce the many different proteins that make up the body. Scientists are only beginning to appreciate, however, the extraordinary degree of control exercised over every step of the production process.

Only about 10 percent of human genes, for example, are actively producing proteins in a given cell at a given time. The remaining 90 percent are silenced by a various mechanisms that act to interfere with gene transcription into messenger RNA or translation of messenger RNA into protein.

In a new study published online May 16 in the journal Nature, a team of scientists at The Wistar Institute and the University of California, San Diego, report identification of an important new gene-silencing mechanism, one that blocks the cellular machinery responsible for translating messenger RNA into proteins at specific genes.

The findings suggests that small bits of RNA known as microRNAs, known to help regulate genes but not used for protein production, may be operating in a completely novel way to prevent genes from producing proteins. MicroRNAs have been implicated in a number of cancers, and the newly outlined gene-silencing mechanism offers promising potential targets for anti-cancer interventions.

"Some microRNAs closely match their sequences against particular messenger RNA sequences to target them for destruction," explains Ramin Shiekhattar, Ph.D., a professor"in the Gene Expression and Regulation Program and the Molecular and Cellular Oncogenesis Program at Wistar and senior author on the new study. "That’s one way we know that microRNAs can silence genes. That mechanism requires extraordinary specificity, however, and we suspected that microRNAs were also acting in some other way to inhibit gene translation into protein. By tracking the associations between molecules involved in generating microRNAs and other molecules in the cell, we uncovered an entirely new pathway
'"/>

Source:The Wistar Institute


Page: 1 2

Related biology news :

1. Newly-discovered class of genes determines ?and restricts ?stem cell fate
2. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
3. Newly Discovered Compound Blocks Known Cancer-Causing Protein
4. Newly discovered pathway might help in design of cancer drugs
5. Newly Discovered Branding Process Helps Immune System Cells Pick Their Fights
6. Newly discovered protein an important tool for sleeping sickness research
7. Newly discovered genetic disease sheds light on bodys water balance
8. Newly Discovered Role for Heart Response Enzyme May Yield Better Heart Failure Therapy
9. Newly recognized gene mutation may reduce seeds, resurrect plants
10. Newly discovered birdlike dinosaur is oldest raptor ever found in South America
11. Fitting in: Newly evolved genes adopt a variety of strategies to remain in the gene pool

Post Your Comments:
(Date:11/8/2009)...TTE, Ind. - Researchers at Purdue University have ...rve fibers in spinal cord injuries using nano-sphe...after an accident. , The synthetic "copolymer mi...ers in diameter, or roughly 100 times smaller than... have been studying how to deliver drugs for cance...
(Date:11/6/2009)...gistration is now open for the Society of Interven...cology (IO) Therapies" Webinar, which will provide...ter treatment of liver tumors, kidney tumor ablati...nization of physicians, scientists and allied heal...lth through pioneering advances in image-guided th...
(Date:11/6/2009)...ov. 6 Auburn Hills, MI-based Law E... installing its locker system and patent-pending B....S. Department of Health and Human Services, Natio...MD. The locker system will support the NIH,s enti... our nation,s medical research agency. The projec...
Breaking Biology News(10 mins):Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Society of Interventional Radiology hosts oncology therapies Webinar, offers resources 2CardioFocus Receives CE Mark for Atrial Fibrillation Ablation Catheter 50857 1CardioFocus Receives CE Mark for Atrial Fibrillation Ablation Catheter 50857 2Burnham Institute for Medical Research and Magellan BioScience Group Inc Announce Drug Discovery Collaboration 12905 1Burnham Institute for Medical Research and Magellan BioScience Group Inc Announce Drug Discovery Collaboration 12905 2Burnham Institute for Medical Research and Magellan BioScience Group Inc Announce Drug Discovery Collaboration 12905 3Symon Announces Revolutionary New Application InView Mobile 26amp 3B 238482 3B 50851 1Symon Announces Revolutionary New Application InView Mobile 26amp 3B 238482 3B 50851 2Symon Announces Revolutionary New Application InView Mobile 26amp 3B 238482 3B 50851 3
...n the cell can serve as an advanced tool for mappi...technique in which non-invasive magnetic resonance... results of this research, conducted by Prof. Mich...egulation Department, were published in the resear...Batya Cohen of the Institute,s Molecular Genetics ...
...Hopkins show that stem cell therapy can be used ef...farction, in pigs. In just two months, stem cells ...ted into the animal,s damaged heart restored heart...percent to 75 percent. , The Hopkins findings, fir...ions of the American Heart Association, are to be ...
... relative excavated last year at Petrified Forest ...ries of how and where the dinosaurs arose more tha... Period. , The animal, one of many creatures from...s thought to be an ancestor of the plant-eating or...tops, which roamed the world millions of years lat...
Other Biology News:Novel live reporting system to track cells 2Stem cell therapy successfully treats heart attack in animals 2Agilent Technologies introduces high-capacity human protein removal system for proteomics research 2Agilent Technologies introduces high-capacity human protein removal system for proteomics research 3Agilent Technologies introduces high-capacity human protein removal system for proteomics research 4
(Date:11/6/2009).... 6 ,, 3Q09 Corpor...enza(TM) E.U. Marketing Authorization to Astellas ...commercial readiness activities Expanded manageme...eting; and Director, Commercial Operations Appoin...udit Committee chairman , Upcoming 2009 Mil...
(Date:11/6/2009)...6 Intarcia Therapeutics, Inc. deli...OS® continuous delivery of exenatide) program... Annual Diabetes Technology Meeting in San Francis...in/prnh/20050301/SFTU126LOGO ) ,, Continuous ...wers Plasma Glucose, HbA1c and Reduces Weight in a...
(Date:11/5/2009).... 5 GenVec, Inc. (Nasdaq...r the third quarter ended September 30, 2009. GenV...share) for the three months ended September 30, 20...er share) in the comparable quarter of 2008. For t...net loss was $14.1 million ($0.15 per share), comp...
(Date:11/5/2009)...ewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bullet...cer, President and CEO of Imagenetix, will be pres...CRO Conference on Thursday, December 3rd, at 10:30...bout LD MICRO ,, LD MICRO is a by-invitation on...lued companies in the micro-cap space. Since 2002,...
Breaking Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2
...s available for technology companies as part of a ... Standards and Technologys Advanced Technology Pr...ligible for an award, and proposals in all technol...s program are a primary source of R&D capital for ...ve an impact across several industrial and social ...
...ed today it has been chosen again to provide scori...nsin-Madisons Camp Randall Stadium and Kohl Center...uipment provided by the South Dakota-based company...eds $5 million with installation scheduled to be c...ll and 2005 Badger basketball seasons. , ,These in...
...ced today they have signed a distribution agreemen...t distributor of advanced clinical in-vitro diagno...ys distribution agreement announced last Wednesday...oal; to create innovative solutions that provide s...hly skilled team provides specialized diagnostic p...
Other Biology Technology:Daktronics to provide Camp Randall and Kohl Center with scoreboards, display systems 2
HP Guaranteed siRNA from QIAGEN
...ells are used for heterologous protein expression ...S2 cell line was derived from a primary culture of...ster embryos (1). This versatile cell line grows...sily adapted to suspension culture. S2 cells are ...
...ression vectors, we in-troduced a new concept, nam...) at tran-scriptional level at the T7 phage promot...fying the plasmid copy number, The main advantage ... retains practically all of the outstanding featur...
...or NTI allows you to store and manage very large a...al relational database. Storing and managing data ...ne tracking and enables you to locate your data ea...egrates seamlessly with Invitrogen's desktop seque...
Biology Products: